18th Jun 2015 07:50
LONDON (Alliance News) - Vectura Group PLC Thursday said Novartis plans to develop a new inhaled dry powder triple therapy for patients with moderate to severe asthma uncontrolled on standard medication which contains a compound that Vectura licensed to the Swiss drugs giant.
QVM149 is a fixed dose, once daily combination of the long-acting beta2-agonist indacaterol, the long-acting muscarinic antagonist glycopyrronium bromide and the inhaled corticosteroid mometasone fuorate. First regulatory filings of QVM149 are planned for 2018, Vectura said.
Glycopyrronium bromide was licensed exclusively to Novartis in April 2005 by Vectura and its co-development partner Sosei. Under the terms of the agreement with Novartis, Vectura is eligible to receive development, filing and approval milestones. In addition, Vectura will receive royalties on products sales in the event of a successful product launch.
Vectura shares were up 0.8% at 175.60 pence early Thursday.
By Steve McGrath; [email protected]; @stevemcgrath1
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
VEC.L